Blood 2002 Sep 1;100(5):1886-93
Yamamoto Y, Wang B, Fukuhara S, Ikehara S, Good RA.
Department of Pediatrics, University of South Florida, All Children's Hospital, St Petersburg, FL; and the First Department of Internal Medicine and First Department of Pathology, Kansai Medical University, Osaka, Japan.
We examined whether mixed allogeneic transplantation with syngeneic plus allogeneic peripheral blood stem cells (PBSCs) is sufficient to interrupt autoimmune processes in BXSB mice and confer a potential therapeutic option for the treatment of patients with autoimmune diseases.
Eight-week-old BXSB mice were lethally irradiated and reconstituted with BALB/c (H-2(d))+BXSB (H-2(b)) PBSCs, in which the number of injected allogeneic progenitor cells was 5 times that of syngeneic progenitor cells.
The survival of mixed PBSC chimeras (BALB/c+BXSB-->BXSB) was 80% at the age of 48 weeks, whereas that of full chimeras (BALB/c-->BXSB) was 90%.
Mixed PBSC transplantation (PBSCT) prevented the production of anti-DNA antibodies and the development of lupus nephritis in BXSB recipients and induced tolerance to both allogeneic and syngeneic antigens.
Moreover, mixed chimeras exhibited immunological functions superior to fully allogeneic chimeras.
On the other hand, increases in the number of BXSB PBSCs resulted in the transfer of lupus nephritis in BXSB+BALB/c-->BALB/c mice.
Thus, the number of hematopoietic progenitor cells from normal mice proved critical to the prevention of autoimmune diseases.
We propose that mixed allogeneic PBSCT for the interruption of the autoimmune process can be carried out by injecting increased numbers of allogeneic normal hematopoietic progenitor cells to prevent the relapse of autoimmune diseases, although it is necessary to decide upon a minimum dose of syngeneic PBSCs to achieve the desired beneficial effects on autoimmunity.